Liver transplantation (LT) is the only therapeutic option for end-stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation f
Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation
β Scribed by Johan Friso Lock; Eugen Schwabauer; Peter Martus; Nikolay Videv; Johann Pratschke; Maciej Malinowski; Peter Neuhaus; Martin Stockmann
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 233 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21973
No coin nor oath required. For personal study only.
β¦ Synopsis
Initial graft function is a major factor influencing the clinical outcome after liver transplantation (LTX), but a reliable method for assessing and predicting graft dysfunction directly after LTX is not available. Ninety-nine patients undergoing deceaseddonor LTX were studied in a prospective pilot study to evaluate the LiMAx test, the indocyanine green test, and conventional biochemical parameters with respect to their sensitivity and prognostic power for the diagnosis of initial graft dysfunction. Patients suffering from initial graft dysfunction (defined as technical complications or primary nonfunction (n ΒΌ 8)) had significantly decreased LiMAx readouts (43 6 18 versus 184 6 98 lg/kg/hour, P < 0.001) immediately after LTX. Univariate analysis also showed significant differences for serum bilirubin, ammonia, glutamate dehydrogenase, and the international normalized ratio (P < 0.05), but multivariate analysis revealed LiMAx as the single independent predictor of initial dysfunction (P ΒΌ 0.008) with an area under the receiver operating characteristic curve (AUROC) of 0.960 (95% confidence interval ΒΌ 0.921-0.998, P < 0.001). In addition, the diagnosis of primary nonfunction (n ΒΌ 3) was evaluated with LiMAx and aspartate aminotransferase (AST) activity on the first postoperative day. The calculated AUROC values were 0.992 (0.975-1.0, P ΒΌ 0.004) for LiMAx and 0.967 (0.929-1.0, P ΒΌ 0.006) for AST. By a combination of test results obtained directly after LTX and on the first day, LiMAx indicated primary nonfunction with a sensitivity of 1.0 (0.31-1.0) and a positive predictive value of 1.0 (0.31-1.0), whereas AST classification showed a sensitivity of 0.67 (0.13-0.98) and a positive predictive value of 0.29 (0.05-0.70). In conclusion, the assessment of initial graft function using the LiMAx test might be effective for identifying critical complications that could threaten graft survival within 24 hours after LTX.
π SIMILAR VOLUMES
Orthotopic liver transplantation (OLT) is the only effective treatment for end-stage liver disease due to primary sclerosing cholangitis (PSC). Recurrence of PSC has recently emerged as a leading cause of allograft failure in the long term. There is limited data on risk factors for recurrence of PSC
clinical appearance of disease is important not only for Whether primary biliary cirrhosis (PBC) recurs after liver transplantation but also for understanding the natliver transplantation has remained an interesting and ural history of PBC. (HEPATOLOGY 1996;24:1079-1084.) controversial issue; reject
Surgical resection and liver transplantation offer a 5-year survival greater than 70% in patients with hepatocellular carcinoma, but the high recurrence rate impairs long-term outcome after resection. Pathological data such as vascular invasion and detection of additional nodules predict recurrence
Bacteremia is a significant cause of morbidity and mortality after liver transplantation. The characterization of the microbiological spectrum of bacteremia after liver transplantation may help physicians in choosing the initial empirical antimicrobial therapy for patients presenting with sepsis. Th
No reliable model for predicting early graft function and patient survival after living donor liver transplantation (LDLT) exists. The aim of this study was to establish a new formula for predicting early graft function and prognosis using technetium-99m galactosyl-human serum albumin (Tc-GSA) liver